Endometrial Thickness Guidelines

Postmenopausal Women

The American College of Radiology recommends that a critical threshold for postmenopausal women is 4 mm or less, which conveys a negative predictive value for endometrial cancer of nearly 100% 1, 2, 3
For postmenopausal women, an endometrial thickness of ≤4 mm is considered normal, and no further evaluation is needed if asymptomatic 1, 2, 3
The American College of Radiology suggests that an endometrial thickness of ≥5 mm prompts endometrial tissue sampling due to increased cancer risk 1, 2, 3
Transvaginal ultrasound (TVUS) is sensitive for measuring endometrial thickness but cannot reliably determine the etiology of thickening 1, 2
The European Society for Medical Oncology uses a slightly more conservative cut-off of ≤3 mm 3

The American College of Radiology states that in premenopausal women, endometrial thickness varies throughout the menstrual cycle, and there is no validated absolute upper limit cutoff 1, 2
Endometrial thickness is NOT a reliable indicator of endometrial pathology in premenopausal women 1, 2
Even with thickness <5 mm, endometrial polyps or other pathology may be present in premenopausal women 1, 2
The thickness changes physiologically with hormonal fluctuations during the menstrual cycle in premenopausal women 1, 2
The American College of Radiology recommends focusing on abnormal echogenicity and texture rather than absolute thickness measurements in premenopausal women 1, 2
Clinical symptoms (abnormal uterine bleeding) should drive further evaluation, not thickness alone in premenopausal women 1, 2

The American College of Radiology advises against applying postmenopausal thresholds to premenopausal women, as the physiology is fundamentally different 1, 2
The American College of Radiology recommends against relying solely on endometrial thickness measurement, and considering echogenicity, texture, and clinical presentation instead 1, 2
In women taking selective progesterone receptor modulators, endometrial thickness may increase without pathological significance 4

The American College of Physicians recommends that combined estrogen-progestogen therapy does not increase endometrial cancer risk (WHI: RH 0.83, 95% CI 0.29-2.32; HERS: RH 0.25, 95% CI 0.05-1.18) 5, 6, 7, 8
Unopposed estrogen increases endometrial cancer risk substantially (RR 2.3, 95% CI 2.1-2.5), with risk increasing to RR 9.5 after 10 years of use, according to the American Academy of Family Physicians 5, 6, 7, 8

The protective effect of progestogen is dose and duration dependent, as stated by the American College of Physicians 5, 6

In women taking selective progesterone receptor modulators, such as ulipristal acetate for fibroids, endometrial thickness may increase without pathological significance, with 11% of patients developing thickness >16 mm during treatment 9

The National Comprehensive Cancer Network recommends against using transvaginal ultrasound as a screening tool in premenopausal patients due to the wide range of endometrial stripe thickness throughout the normal menstrual cycle, as stated by the Journal of the National Comprehensive Cancer Network 10, 11
In premenopausal women with Lynch syndrome, the National Comprehensive Cancer Network does not recommend transvaginal ultrasound screening for endometrial cancer due to the wide range of normal endometrial thickness throughout the menstrual cycle, and instead advises education on prompt reporting of abnormal uterine bleeding to trigger endometrial biopsy regardless of ultrasound findings 10, 11

The American College of Radiology recommends transvaginal ultrasound (TVUS) with Doppler as the primary imaging modality for evaluating structural abnormalities in premenopausal women with abnormal uterine bleeding, assessing for structural causes such as polyps, adenomyosis, and leiomyomas 12, 13, 14
TVUS should assess for endometrial echogenicity and texture, as well as vascularity patterns using color/power Doppler, to evaluate for structural abnormalities in premenopausal women with abnormal uterine bleeding 12, 13, 14
If the endometrium cannot be completely evaluated by ultrasound, consider MRI with diffusion-weighted imaging for superior tissue contrast resolution, particularly in cases where patient body habitus, uterine position, or presence of fibroids/adenomyosis limit ultrasound evaluation 12, 13, 14

The American College of Radiology suggests that clinical symptoms, rather than thickness alone, should drive further evaluation in symptomatic patients, with TVUS used to assess for structural abnormalities and endometrial sampling considered based on risk factors for endometrial cancer 12, 13, 14
Endometrial sampling should be considered based on risk factors for endometrial cancer, such as age >45 years, obesity, and unopposed estrogen exposure, rather than thickness measurements 12, 13, 14

In patients taking ulipristal acetate for fibroids, endometrial thickness >16 mm may occur without pathological significance, and ultrasound measurement of endometrial thickness is not clinically indicated during treatment courses 15
The mean endometrial thickness at the end of the first treatment course with ulipristal acetate is approximately 8 mm, similar to placebo 15

The absence of vascularity on Doppler does not exclude pathology, as avascular retained products of conception or polyps can occur 16

The most common structural sources of abnormal uterine bleeding in premenopausal women are polyps, adenomyosis, and leiomyomas, which can be detected by assessing morphology and echogenicity patterns on TVUS, rather than thickness cutoffs 12, 13, 14